Molecular Diagnostics: Methods and Limitations

Hereditary Breast Cancer

Volumn , Issue , 2007, Pages 179-206

  Tavtigian, Sean V ^a   LeCalvez Kelm, Florence ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61849091085     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420020366-15     Document Type: Chapter

References (136)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182):66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559):789-792.
3. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12(3):333-337.
4. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3):676-689.
5. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108(2):171-182.
6. Nielsen DA, Novoradovsky A, Goldman D. SSCP primer design based on single-strand DNA structure predicted by a DNA folding program. Nucleic Acids Res 1995; 23(12): 2287-2291.
7. Orita M, Iwahana H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A 1989; 86(8):2766-2770.
8. Suzuki Y, Orita M, Shiraishi M, et al. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990; 5(7):1037-1043.
9. Berta P, Hawkins JR, Sinclair AH, et al. Genetic evidence equating SRY and the testisdetermining factor. Nature 1990; 348(6300):448-450.
10. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8(4): 399-404.
11. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996; 334(3):137-142.
12. Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 sitespecific breast cancer families. Nat Genet 1996; 13(1):120-122.
13. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38(8):873-875.
14. Andersen PS, Jespersgaard C, Vuust J, et al. High-throughput single strand conformation polymorphism mutation detection by automated capillary array electrophoresis: validation of the method. Hum Mutat 2003; 21(2):116-122.
15. Doi K, Doi H, Noiri E, et al. High-throughput single nucleotide polymorphism typing by fluorescent single-strand conformation polymorphism analysis with capillary electrophoresis. Electrophoresis 2004; 25(6):833-838.
16. Gross E, Arnold N, Goette J, et al. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP, and DHPLC. Hum Genat 1999; 105(1-2):72-78.
17. Eng C, Brody LC, Wagner TM, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001; 38(12):824-833.
18. Andrulis IL, Anton-Culver H, Beck J, et al. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 2002; 20(1):65-73.
19. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002; 4(1):R2.
20. Fischer SG, Lerman LS. Length-independent separation of DNA restriction fragments in two-dimensional gel electrophoresis. Cell 1979; 16(1):191-200.
21. Fischer SG, Lerman LS. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory. Proc Natl Acad Sci U S A 1983; 80(6):1579-1583.
22. Myers RM, Fischer SG, Lerman LS, et al. Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis. Nucleic Acids Res 1985; 13(9):3131-3145.
23. Myers RM, Fischer SG, Maniatis T, et al. Modification of the melting properties of duplex DNA by attachment of a GC-rich DNA sequence as determined by denaturing gradient gel electrophoresis. Nucleic Acids Res 1985; 13(9):3111-3129.
24. Sheffield VC, Cox DR, Lerman LS, et al. Attachment of a 40-base-pair G þ C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci U S A 1989; 86(1):232-236.
25. van der Hout AH, van den Ouweland AM, van der Luijt RB, et al. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 2006; 27(7):654-666.
26. Van Orsouw NJ, Li D, van der Vlies P, et al. Mutational scanning of large genes by extensive PCR multiplexing and two-dimensional electrophoresis: application to the RB1 gene. Hum Mol Genet 1996; 5(6):755-761.
27. Marsh DJ, Roth S, Lunetta KL, et al. Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res 1997; 57(22):5017-5021.
28. Rines RD, van Orsouw NJ, Sigalas I, et al. Comprehensive mutational scanning of the p53 coding region by two-dimensional gene scanning. Carcinogenesis 1998; 19(6):979-984.
29. van Orsouw NJ, Dhanda RK, Elhaji Y, et al. A highly accurate, low cost test for BRCA1 mutations. J Med Genet 1999; 36(10):747-753.
30. Bounpheng M, McGrath S, Macias D, et al. Rapid, inexpensive scanning for all possible BRCA1 and BRCA2 gene sequence variants in a single assay: implications for genetic testing. J Med Genet 2003; 40(4):e33.
31. McGrath SB, Bounpheng M, Torres L, et al. High-speed, multicolor fluorescent twodimensional gene scanning. Genomics 2001; 78(1-2):83-90.
32. Marsh DJ, Dahia PL, Caron S, et al. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 1998; 35(11):881-885.
33. Li Q, Liu Z, Monroe H, et al. Integrated platform for detection of DNA sequence variants using capillary array electrophoresis. Electrophoresis 2002; 23(10):1499-1511.
34. Bhattacharyya A, Lilley DM. The contrasting structures of mismatched DNA sequences containing looped-out bases (bulges) and multiple mismatches (bubbles). Nucleic Acids Res 1989; 17(17):6821-6840.
35. Nagamine CM, Chan K, Lau YF. A PCR artifact: generation of heteroduplexes. Am J Hum Genet 1989; 45(2):337-339.
36. Rommens J, Kerem BS, Greer W, et al. Rapid nonradioactive detection of the major cystic fibrosis mutation. Am J Hum Genet 1990; 46(2):395-396.
37. Keen J, Lester D, Inglehearn C, et al. Rapid detection of single base mismatches as heteroduplexes on Hydrolink gels. Trends Genet 1991; 7(1):5.
38. Perry DJ, Carrell RW. Hydrolink gels: a rapid and simple approach to the detection of DNA mutations in thromboembolic disease. J Clin Pathol 1992; 45(2):158-160.
39. Soto D, Sukumar S. Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Methods Appl 1992; 2(1):96-98.
40. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A 1993; 90(21):10325-10329.
41. Ganguly T, Dhulipala R, Godmilow L, et al. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. Hum Genet 1998; 102(5):549-556.
42. Edwards SM, Kote-Jarai Z, Hamoudi R, et al. An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD). Hum Mutat 2001; 17(3):220-232.
43. Spitzer E, Abbaszadegan MR, Schmidt F, et al. Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. Int J Cancer 2000; 85(4):474-481.
44. Seo JH, Cho DY, Ahn SH, et al. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer. Hum Mutat 2004; 24(4):350.
45. Rozycka M, Collins N, Stratton MR, et al. Rapid detection of DNA sequence variants by conformation-sensitive capillary electrophoresis. Genomics 2000; 70(1):34-40.
46. Davies H, Dicks E, Stephens P, et al. High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison. Genomics 2006; 87(3):427-432.
47. Bhattacharyya A, Lilley DM. Single base mismatches in DNA. Long- and short-range structure probed by analysis of axis trajectory and local chemical reactivity. J Mol Biol 1989; 209(4):583-597.
48. Britten RJ, Smith J. A bovine genome. Carnegie Inst Wash Yearbook 1970; 68:378-386.
49. Davidson EH, Hough BR, Amenson CS, et al. General interspersion of repetitive with nonrepetitive sequence elements in the DNA of Xenopus. J Mol Biol 1973; 77(1):1-23.
50. Hardies SC, Wells RD. Preparative fractionation of DNA restriction fragments by reversed phase column chromatography. Proc Natl Acad Sci U S A 1976; 73(9): 3117-3121.
51. Usher DA. Reverse-phase HPLC of DNA restriction fragments and ribooligonucleotides on uncoated Kel-F powder. Nucleic Acids Res 1979; 6(6):2289-2306.
52. Huber CG, Oefner PJ, Preuss E, et al. High-resolution liquid chromatography of DNA fragments on non-porous poly(styrene-divinylbenzene) particles. Nucleic Acids Res 1993; 21(5):1061-1066.
53. Oefner PJ, Underhill PA. Comparative DNA sequencing by denaturing high-performance liquid chromatography (DHPLC). Am J Hum Genet 1995; 57s:A266.
54. O’Donovan MC, Oefner PJ, Roberts SC, et al. Blind analysis of denaturing highperformance liquid chromatography as a tool for mutation detection. Genomics 1998; 52(1): 44-49.
55. Wagner T, Stoppa-Lyonnet D, Fleischmann E, et al. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 1999; 62(3): 369-376.
56. Underhill PA, Jin L, Lin AA, et al. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res 1997; 7(10):996-1005.
57. Sevilla C, Moatti JP, Julian-Reynier C, et al. Testing for BRCA1 mutations: a costeffectiveness analysis. Eur J Hum Genet 2002; 10(10):599-606.
58. Schollen E, Dequeker E, McQuaid S, et al. Diagnostic DHPLC Quality Assurance (DDQA): a collaborative approach to the generation of validated and standardized methods for DHPLC-based mutation screening in clinical genetics laboratories. Hum Mutat 2005; 25(6): 583-592.
59. Shenk TE, Rhodes C, Rigby PW, et al. Biochemical method for mapping mutational alterations in DNA with S1 nuclease: the location of deletions and temperature-sensitive mutations in simian virus 40. Proc Natl Acad Sci U S A 1975; 72(3):989-993.
60. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science 1985; 230(4731):1242-1246.
61. Winter E, Yamamoto F, Almoguera C, et al. A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells. Proc Natl Acad Sci U S A 1985; 82(22):7575-7579.
62. Cotton RG, Rodrigues NR, Campbell RD. Reactivity of cytosine and thymine in single-basepair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci U S A 1988; 85(12):4397-4401.
63. Verpy E, Biasotto M, Meo T, et al. Efficient detection of point mutations on color-coded strands of target DNA. Proc Natl Acad Sci U S A 1994; 91(5):1873-1877.
64. Verpy E, Biasotto M, Brai M, et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angioedema. Am J Hum Genet 1996; 59(2):308-319.
65. Ricevuto E, Sobol H, Stoppa-Lyonnet D, et al. Diagnostic strategy for analytical scanning of BRCA1 gene by fluorescence-assisted mismatch analysis using large, bifluorescently labeled amplicons. Clin Cancer Res 2001; 7(6):1638-1646.
66. Pages S, Caux V, Stoppa-Lyonnet D, et al. Screening of male breast cancer and of breastovarian cancer families for BRCA2 mutations using large bifluorescent amplicons. Br J Cancer 2001; 84(4):482-488.
67. Tessitore A, Di Rocco ZC, Cannita K, et al. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. Genes Chromosomes Cancer 2002; 35(1):86-91.
68. De Galitiis F, Cannita K, Tessitore A, et al. Novel P53 mutations detected by FAMA in colorectal cancers. Ann Oncol 2006; 17(Suppl 7):vii78-vii83.
69. Liew M, Pryor R, Palais R, et al. Genotyping of single-nucleotide polymorphisms by highresolution melting of small amplicons. Clin Chem 2004; 50(7):1156-1164.
70. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 2004; 50(10):1748-1754.
71. http://www.ngrl.org.uk/Wessex/downloads.htm
72. Roest PA, Roberts RG, van der Tuijn AC, et al. Protein truncation test (PTT) to rapidly screen the DMD gene for translation terminating mutations. Neuromuscul Disord 1993; 3(5-6):391-394.
73. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329(27):1982-1987.
74. Neuhausen SL, Ostrander EA. Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. Genet Test 1997; 1(2):75-83.
75. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998; 16(5):1969-1977.
76. Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995; 10(2):208-212.
77. Garvin AM, Attenhofer-Haner M, Scott RJ. BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients. J Med Genet 1997; 34(12):990-995.
78. Garvin AM. A complete protein truncation test for BRCA1 and BRCA2. Eur J Hum Genet 1998; 6(3):226-234.
79. Baker KE, Parker R. Nonsense-mediated mRNA decay: terminating erroneous gene expression. Curr Opin Cell Biol 2004; 16(3):293-299.
80. Ozcelik H, Antebi YJ, Cole DE, et al. Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation. Hum Genet 1996; 98(3):310-312.
81. Maxam AM, Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci U S A 1977; 74(2):560-564.
82. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74(12):5463-5467.
83. Smith LM, Fung S, Hunkapiller MW, et al. The synthesis of oligonucleotides containing an aliphatic amino group at the 50 terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis. Nucleic Acids Res 1985; 13(7):2399-2412.
84. Smith LM, Sanders JZ, Kaiser RJ, et al. Fluorescence detection in automated DNA sequence analysis. Nature 1986; 321(6071):674-679.
85. Prober JM, Trainor GL, Dam RJ, et al. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 1987; 238(4825):336-341.
86. Parker LT, Zakeri H, Deng Q, et al. AmpliTaq DNA polymerase, FS dye-terminator sequencing: analysis of peak height patterns. Biotechniques 1996; 21(4):694-699.
87. Chadwick RB, Conrad MP, McGinnis MD, et al. Heterozygote and mutation detection by direct automated fluorescent DNA sequencing using a mutant Taq DNA polymerase. Biotechniques 1996; 20(4):676-683.
88. Yan H, Kinzler KW, Vogelstein B. Techsight. Genetic testing-present and future. Science 2000; 289(5486):1890-1892.
89. Tabor S, Richardson CC. A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides. Proc Natl Acad Sci U S A 1995; 92(14):6339-6343.
90. Reeve MA, Fuller CW. A novel thermostable polymerase for DNA sequencing. Nature 1995; 376(6543):796-797.
91. Rosenblum BB, Lee LG, Spurgeon SL, et al. New dye-labeled terminators for improved DNA sequencing patterns. Nucleic Acids Res 1997; 25(22):4500-4504.
92. Duthie RS, Kalve IM, Samols SB, et al. Novel cyanine dye-labeled dideoxynucleoside triphosphates for DNA sequencing. Bioconjug Chem 2002; 13(4):699-706.
93. Phelps RS, Chadwick RB, Conrad MP, et al. Efficient, automatic detection of heterozygous bases during large-scale DNA sequence screening. Biotechniques 1995; 19(6):984-989.
94. Tavtigian SV, Oliphant A, Shattuck-Eidens D, et al. Genomic organization, functional analysis, and mutation screening of BRCA1 and BRCA2. In: Fortner JG, Sharp PA, eds. Accomplishments in Cancer Research 1996. Philadelphia, New York: Lippincott-Raven, 1997: 189-204.
95. Bonfield JK, Rada C, Staden R. Automated detection of point mutations using fluorescent sequence trace subtraction. Nucleic Acids Res 1998; 26(14):3404-3409.
96. Staden R, Beal KF, Bonfield JK. The Staden package, 1998. Methods Mol Biol 2000;; 132: 115-130.
97. Zhang J, Wheeler DA, Yakub I, et al. SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol 2005; 1(5):e53.
98. Hacia JG. Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 1999; 21(1 suppl):42-47.
99. Hacia JG, Brody LC, Chee MS, et al. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet 1996; 14(4):441-447.
100. Hacia JG, Sun B, Hunt N, et al. Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. Genome Res 1998; 8(12): 1245-1258.
101. Karaman MW, Groshen S, Lee CC, et al. Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarrays. Nucleic Acids Res 2005; 33(3):e33.
102. Shumaker JM, Metspalu A, Caskey CT. Mutation detection by solid phase primer extension. Hum Mutat 1996; 7(4):346-354.
103. Kurg A, Tonisson N, Georgiou I, et al. Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. Genet Test 2000; 4(1):1-7.
104. Tonisson N, Kurg A, Kaasik K, et al. Unravelling genetic data by arrayed primer extension. Clin Chem Lab Med 2000; 38(2):165-170.
105. Tonisson N, Zernant J, Kurg A, et al. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A 2002; 99(8):5503-5508.
106. Kringen P, Bergamaschi A, Due EU, et al. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. Biotechniques 2005; 39(5): 755-761.
107. Le Calvez F, Ahman A, Tonisson N, et al. Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. Clin Chem 2005; 51(7):1284-1287.
108. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98(3):503-517.
109. Kan YW, Dozy AM. Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. Proc Natl Acad Sci U S A 1978; 75(11): 5631-5635.
110. Puget N, Torchard D, Serova-Sinilnikova OM, et al. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 1997; 57(5):828-831.
111. Swensen J, Hoffman M, Skolnick MH, et al. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet 1997; 6(9): 1513-1517.
112. Robinson MD, Chu CE, Turner G, et al. Exon deletions and duplications in BRCA1 detected by semiquantitative PCR. Genet Test 2000; 4(1):49-54.
113. Hofmann W, Gorgens H, John A, et al. Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. Hum Mutat 2003; 22(1):103-104.
114. Charbonnier F, Raux G, Wang Q, et al. Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 2000; 60(11): 2760-2763.
115. Casilli F, Di Rocco ZC, Gad S, et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 2002; 20(3):218-226.
116. Tournier I, Paillerets BB, Sobol H, et al. Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 2004; 64(22):8143-8147.
117. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30(12):e57.
118. Taylor CF, Charlton RS, Burn J, et al. Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. Hum Mutat 2003; 22(6):428-433.
119. Montagna M, Dalla Palma M, Menin C, et al. Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 2003; 12(9):1055-1061.
120. Hogervorst FB, Nederlof PM, Gille JJ, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003; 63(7):1449-1453.
121. Bunyan DJ, Eccles DM, Sillibourne J, et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 2004; 91(6):1155-1159.
122. Agata S, Dalla Palma M, Callegaro M, et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet 2005; 42(10):e64.
123. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, et al. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 1999; 59(2):455-461.
124. Gad S, Caux-Moncoutier V, Pages-Berhouet S, et al. Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families. Oncogene 2002; 21(44):6841-6847.
125. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295(12):1379-1388.
126. Hendrickson BC, Judkins T, Ward BD, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20, 000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer 2005; 43(3):309-313.
127. Mazoyer S, Dunning AM, Serova O, et al. A polymorphic stop codon in BRCA2. Nat Genet 1996; 14(3):253-254.
128. Goldgar DE, Easton DF, Deffenbaugh AM, et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BCA1 and BRCA2. Am J Hum Genet 2004; 75(4):535-544.
129. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006; 43(4):295-305.
130. Tavtigian SV, Samollow PB, de Silva D, et al. An analysis of unclassified missense substitutions in human BRCA1. Fam Cancer 2006; 5(1):77-88.
131. Chenevix-Trench G, Healey S, Lakhani S, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 2006; 66(4):2019-2027.
132. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9(3):221-236.
133. Fleming MA, Potter JD, Ramirez CJ, et al. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A 2003; 100(3):1151-1156.
134. Ramirez CJ, Fleming MA, Potter JD, et al. Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes. Oncogene 2004; 23(9):1780-1788.
135. Abkevich V, Zharkikh A, Deffenbaugh A, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Gen 2004; 41:492-507.
136. http://research.nhgri.nih.gov/bic/